+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Critical Limb Ischemia Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • ID: 4987124
  • Report
  • January 2022
  • Region: Global
  • 110 Pages
  • Mordor Intelligence


  • Abbott Laboratories
  • Cynata Therapeutics Ltd
  • Eli Lilly and Company
  • LimFlow SA
  • Medtronic plc
  • Rexgenero Ltd.

The critical limb ischemia treatment market studied was projected to grow with a CAGR of nearly 8.3% over the forecast period. The major factor attributing to the growth of the market is the increasing prevalence of critical limb ischemia. The key factors responsible for critical limb ischemia disease are increasing geriatric population, who are more vulnerable to the development of these conditions, and others include diabetes, obesity, sedentary lifestyle, smoking, and increased blood pressure. Untreated critical limb ischemia can lead to amputation of the specific limb. The growing incidence of critical limb ischemia is anticipated to drive the demand for its treatment, which, in line, is projected to propel the growth of the critical limb ischemia treatment market globally. Furthermore, the growing investments in research and development programs by the medical devices and pharmaceutical companies are boosting the market growth. However, drug failure and drug recalls are the major drawbacks for market growth.

Key Market Trends

Medications Segment is expected to Grow at a Faster Rate over the Forecast Period

  • The medications segment of the critical limb ischemia treatment market includes antihypertensive agents, antiplatelet drugs, antithrombotic agents, lipid-lowering agents, and others.
  • In critical limb ischemia patients who are not flexible for surgical or endovascular revascularization or patients with whom revascularisation attempts have been ineffective, medication is the only way to reduce the pain and treat the patients. Several studies have shown that medication reduced ischaemic rest pain, ulcer size and the need for amputation.
  • As the geriatric population increases the patient pool also increases which in turn boosts the market growth.

North America Dominates the Market and Expected to do Same in the Forecast Period

North America is expected to dominate the overall critical limb ischemia (CIL) treatment market, throughout the forecast period. The market growth is due to the factors such as the presence of key players, high prevalence of CIL patients in the region, established healthcare infrastructure, and availability of branded drugs are some of the key factors accountable for its large share in the market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth. The United States holds the largest share of the market. The United States has a unique healthcare system among developed countries. However, the cost of hospitals is very high in the country; the government or private insurance covers it. The rising prevalence of CIL and the increasing geriatric population in the country are the prime factors responsible for the growth of the market in the country.

Competitive Landscape

The critical limb ischemia treatment market is moderately competitive and consists of several major players. Some of the companies which are currently domianting the market are Medtronic plc, Abbott Laboratories, Rexgenero Ltd., LimFlow SA, Cardiovascular Systems, Inc., and ThermoGenesis Holdings, Inc

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.
Note: Product cover images may vary from those shown


  • Abbott Laboratories
  • Cynata Therapeutics Ltd
  • Eli Lilly and Company
  • LimFlow SA
  • Medtronic plc
  • Rexgenero Ltd.

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in prevalence of Critical Limb Ischemia
4.2.2 Improvement in health care infrastructure
4.3 Market Restraints
4.3.1 Drug Failure and Drug Recalls
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5.1 By Treatment Type
5.1.1 Devices Embolic Protection Devices Peripheral Dilatation Systems
5.1.2 Medications Antiplatelet Drugs Antihypertensive Agents Lipid-lowering Agents Others
5.1.3 Surgery
5.2 Geography
5.2.1 North America United States Canada Mexico
5.2.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.2.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.2.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.2.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Medtronic plc
6.1.2 LimFlow SA
6.1.3 Cynata Therapeutics Ltd
6.1.4 Cardiovascular Systems, Inc.
6.1.5 Eli Lilly and Company
6.1.6 Abbott Laboratories
6.1.7 Rexgenero Ltd.
6.1.8 ThermoGenesis Holdings, Inc
6.1.9 Teva Pharmaceuticals
Note: Product cover images may vary from those shown

A selection of companies mentioned in this report includes:

  • Medtronic plc
  • LimFlow SA
  • Cynata Therapeutics Ltd
  • Cardiovascular Systems, Inc.
  • Eli Lilly and Company
  • Abbott Laboratories
  • Rexgenero Ltd.
  • ThermoGenesis Holdings, Inc
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown